FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 313:905-909 October 10, 1985 Number 15 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We conducted a randomized, double-blind clinical trial of atenolol as compared with placebo in the treatment of patients hospitalized with the alcohol withdrawal syndrome. In addition to receiving customary therapy, 61 patients were randomly assigned to receive atenolol, and 59 to receive placebo. Outcome was assessed daily by the measurement of nine features in three categories: vital signs, clinical signs (e.g., tremor), and behavioral signs (e.g., agitation and anxiety). Compared with placebo patients, atenolol patients had a significant reduction in the mean length of hospital stay (four as compared with five days, P less than 0.02). On each treatment day, significantly fewer patients receiving atenolol required concomitant benzodiazepines, and patients receiving placebo required a significantly higher mean daily dose of benzodiazepines. Among patients who had withdrawal symptoms at base line, vital signs became normal more rapidly in the patients receiving atenolol, and their abnormal behavior and clinical characteristics also resolved more rapidly. We conclude that atenolol is helpful in the treatment of patients with the alcohol withdrawal syndrome.

This article has been cited by other articles:

• McKeon, A, Frye, M A, Delanty, N. (2008). The alcohol withdrawal syndrome. J. Neurol. Neurosurg. Psychiatry 79: 854-862 [Abstract] [Full Text]  
• Lansford, C. D., Guerriero, C. H., Kocan, M. J., Turley, R., Groves, M. W., Bahl, V., Abrahamse, P., Bradford, C. R., Chepeha, D. B., Moyer, J., Prince, M. E., Wolf, G. T., Aebersold, M. L., Teknos, T. N. (2008). Improved Outcomes in Patients With Head and Neck Cancer Using a Standardized Care Protocol for Postoperative Alcohol Withdrawal. Arch Otolaryngol Head Neck Surg 134: 865-872 [Abstract] [Full Text]  
• Williams, D., Lewis, J., McBride, A. (2001). A comparison of rating scales for the alcohol-withdrawal syndrome. Alcohol Alcohol 36: 104-108 [Abstract] [Full Text]  
• Mayo-Smith, M. F. (1997). Pharmacological Management of Alcohol Withdrawal: A Meta-analysis and Evidence-Based Practice Guideline. JAMA 278: 144-151 [Abstract]  
• Fuller, R. K., Gordis, E. (1994). Refining the Treatment of Alcohol Withdrawal. JAMA 272: 557-558 [Abstract]  
• Michels, R., Marzuk, P. M. (1993). Progress in Psychiatry- Second of Two Parts. NEJM 329: 628-638 [Full Text]  
• Horwitz, R. I., Gottlieb, L. D., Kraus, M. L. (1989). The Efficacy of Atenolol in the Outpatient Management of the Alcohol Withdrawal Syndrome: Results of a Randomized Clinical Trial. Arch Intern Med 149: 1089-1093 [Abstract]  
• Mehta, J. L., Lopez, L. M. (1987). Rebound Hypertension Following Abrupt Cessation of Clonidine and Metoprolol: Treatment With Labetalol. Arch Intern Med 147: 389-390 [Abstract]